Citations

Showing 10 of 108083 citations.

Thoracic Volumes Correlated With Pulmonary Function Tests in Adult Scoliosis Patients Following Different Treatments in Adolescence
Lee, Po-Chih, Ledonio, Charles, Erdman, Arthur G. , Larson, A. Noelle , Polly, David W.

Mayo Clinic

2017 Design of Medical Devices Conference | October 31, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2017-3364 Get It

In clinical settings, doctors classify pulmonary disorders into two main categories, obstructive lung disease and restrictive lung disease. The former is characterized by the airway obstruction which is associated with several disorders like chronic bronchitis, asthma, bronchiectasis, and emphysema [1]. The latter is caused by different conditions where one of the triggers is tied to the spine deformity. In general, a pulmonary function test (PFT) [2] is used to evaluate and diagnose lung function, and physicians depend on the test results to identify the disease patterns of the patients (obstructive or restrictive lung disease). In the PFT, some parameters including total lung capacity (TLC), vital capacity (VC), and residual volume (RV) can infer the lung volume and lung capacity. Other parameters, such as forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1), are often employed to assess the pulmonary mechanics. Scoliosis is an abnormal lateral curvature of the spine which involves not only the curvature from side to side but also an axial rotation of the vertebrae. Restrictive lung disease often happens in scoliosis patients, especially with severe spine deformity. Spine deformity if left untreated may lead to progression of the spinal curve, respiratory complications, and the reduction of life expectancy due to the decrease in thoracic volume for lung expansion. However, the relationship between thoracic volume and pulmonary function is not broadly discussed, and anatomic abnormalities in spine deformity (ex: scoliosis, kyphosis, and osteoporosis) can affect thoracic volume. Adequate thoracic volume is needed to promote pulmonary function. Previous literature has shown that the deformity of the thoracic rib cage will have detrimental effects on the respiratory function in adolescent idiopathic scoliosis patients [3–4]. In this paper, we aim to correlate thoracic volume and the parameters in PFTs in adult scoliosis patients 25–35 years after receiving treatments during their adolescence, either with physical bracing or spinal fusion surgery.
Is there clinical consensus in defining weight restoration for adolescents with anorexia nervosa?
Lebow, Jocelyn , Sim, Leslie , Accurso, Erin C. , Sim, Leslie A , Accurso, Erin C , Lebow, Jocelyn

Mayo Clinic

Eating Disorders | October 31, 2017 | Volume: 26 | Issue: 3 | Pages: 270-277

10.1080/10640266.2017.1388664 | PMID 29087249 Get It

Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surgery in adults
Guay, Joanne, Kopp, Sandra L. , Kopp, Sandra , Johnson, Rebecca L.

Mayo Clinic

Cochrane Database of Systematic Reviews | October 31, 2017 | Volume: 2017 | Issue: 10 | Pages: No page available

10.1002/14651858.cd011608.pub2 | PMID 29087547 Get It

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin
Vinereanu, Dragoş , Mulder, Hillary , Hanna, Michael G. , Wallentin, Lars , Granger, Christopher B. , Alexander, John H. , Lópes, Renato D. , Hanna, Michael , de Barros E Silva, Pedro G M, Atar, Dan, Granger, Christopher B , Gersh, Bernard J. , Silva, Pedro Gabriel Melo de Barros e , Atar, Dan , Mulder, Hillary

Mayo Clinic

Stroke | October 31, 2017 | Volume: 48 | Issue: 12 | Pages: 3266-3273

10.1161/strokeaha.117.017574 | PMID 29089455 Get It

Background and Purpose— Few data exist on the long-term outcomes of patients with spontaneous echo contrast (SEC), left atrial/left atrial appendage (LA/LAA) thrombus, and complex aortic plaque (CAP), in patients with atrial fibrillation receiving oral anticoagulation. We explored the relationship between these 3 echocardiographic findings and clinical outcomes, and the comparative efficacy and safety of apixaban and warfarin for each finding. Methods— Patients from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) with SEC, LA/LAA thrombus, or CAP diagnosed by either transthoracic or transesophageal echocardiography were compared with patients with none of these findings on transesophageal echocardiography. Results— A total of 1251 patients were included: 217 had SEC, 127 had LA/LAA thrombus, 241 had CAP, and 746 had none. The rates of stroke/systemic embolism were not significantly different among patients with and without these echocardiographic findings (hazard ratio, 0.96; 95% confidence interval, 0.25–3.60 for SEC; hazard ratio, 1.27; 95% confidence interval, 0.23–6.86 for LA/LAA thrombus; hazard ratio, 2.21; 95% confidence interval, 0.71–6.85 for CAP). Rates of ischemic stroke, myocardial infarction, cardiovascular death, and all-cause death were also not different between patients with and without these findings. For patients with either SEC or CAP, there was no evidence of a differential effect of apixaban over warfarin. For patients with LA/LAA thrombus, there was also no significant interaction, with the exception of all-cause death and any bleeding where there was a greater benefit of apixaban compared with warfarin among patients with no LA/LAA thrombus. Conclusions— In anticoagulated patients with atrial fibrillation and risk factors for stroke, echocardiographic findings do not seem to add to the risk of thromboembolic events. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00412984.
Mystery Case: Widespread plexiform neurofibromas in neurofibromatosis type 1
Grimsrud, Kate W., Porter, Alyx B.

Mayo Clinic

Neurology | October 30, 2017 | Volume: 89 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000004595 | PMID 29084928 Get It

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Renfro, Lindsay A. , Hurwitz, Herbert I. , Safran, Howard , Guarino, Michael J., Kim, George P., Hecht, J. Randolph, Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., Díaz, Luis A. , Diaz, Luis A , Grothey, Axel , Strosberg, Jonathan , Marshall, John L , Wang, Wenquan

Mayo Clinic

Clinical Cancer Research | October 30, 2017 | Volume: 24 | Issue: 2 | Pages: 316-325

10.1158/1078-0432.ccr-17-1558 | PMID 29084918 Get It

Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR.
Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution
Breitenstein, Matthew K. , Pathak, Jyotishman , Zhang, Rui , Liu, Hongfang , Maxwell, Kara N.

Mayo Clinic

Clinical and Translational Science | October 30, 2017 | Volume: 11 | Issue: 1 | Pages: 85-92

10.1111/cts.12514 | PMID 29084368 Get It

AbstractPrecision medicine is at the forefront of biomedical research. Cancer registries provide rich perspectives and electronic health records (EHRs) are commonly utilized to gather additional clinical data elements needed for translational research. However, manual annotation is resource‐intense and not readily scalable. Informatics‐based phenotyping presents an ideal solution, but perspectives obtained can be impacted by both data source and algorithm selection. We derived breast cancer (BC) receptor status phenotypes from structured and unstructured EHR data using rule‐based algorithms, including natural language processing (NLP). Overall, the use of NLP increased BC receptor status coverage by 39.2% from 69.1% with structured medication information alone. Using all available EHR data, estrogen receptor‐positive BC cases were ascertained with high precision (P = 0.976) and recall (R = 0.987) compared with gold standard chart‐reviewed patients. However, status negation (R = 0.591) decreased 40.2% when relying on structured medications alone. Using multiple EHR data types (and thorough understanding of the perspectives offered) are necessary to derive robust EHR‐based precision medicine phenotypes.
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Chinnaiyan, Prakash , Won, Minhee , Wen, Patrick Y. , Rojiani, Amyn M. , Werner‐Wasik, Maria, Shih, Helen A. , Ashby, Lynn S., Yu, Hsiang-Hsuan Michael, Stieber, Volker W. , Malone, Shawn , Fiveash, John B. , Mohile, Nimish, Ahluwalia, Manmeet S. , Wendland, Merideth M, Stella, Philip J., Kee, Andrew Y., Tsai, Ya-Yu , Shih, Helen A , Wen, Patrick Yung , Mehta, Minesh P. , Ahluwalia, Manmeet S

Mayo Clinic

Neuro-Oncology | October 30, 2017 | Volume: 20 | Issue: 5 | Pages: 666-673

10.1093/neuonc/nox209 | PMID 29126203 Get It

Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T‐cell and B‐cell lymphoproliferative disorders
Comfere, Nneka I. , Sundram, Uma , Hurley, M. Yadira , Swick, Brian L. , Comfere, Nneka, Hurley, Maria Yadira

Mayo Clinic

Journal of Cutaneous Pathology | October 30, 2017 | Volume: 45 | Issue: 1 | Pages: 39-47

10.1111/cup.13072 | PMID 29084365 Get It

BackgroundAppropriate use criteria have been developed for many tests using expert judgment, evidence‐based practice and clinical experience. In this context, we report the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected.MethodsAn Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). We conducted, summarized and presented a relevant literature search to an audience of 144 dermatopathologists with a variety of practice experiences at the 53rd Annual Meeting of the ASDP in Chicago, IL.ResultsTwenty‐seven clinical scenarios for LPDs (13 T‐cell and 14 B‐cell) were defined. Forty relevant studies for T‐cell receptor gene clonality assays and 20 relevant studies for IgH/IgK clonality assays were identified. Audience response data from participating dermatopathologists reflected a wide variety of approaches to the application of clonality assays in the evaluation of LPDs, based on practice setting, personal experience and test availability.ConclusionsOur clinical scenario analysis and literature review revealed well‐supported clinical scenarios and identified opportunities for additional research to further define the utility of clonality assays in some clinical scenarios.
Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis
Molica, Stefano , Giannarelli, Diana , Mirabelli, Rosanna, Levato, Luciano , Kay, Neil E. , Shanafelt, Tait D , Kay, Neil E , Molica, Stefano , Mirabelli, Rosanna, Shanafelt, Tait D.

Mayo Clinic

Blood | October 30, 2017 | Volume: 131 | Issue: 3 | Pages: 365-368

10.1182/blood-2017-09-806034 | PMID 29084773 Get It